EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu Fierce Pharma
Covered in this story
Summary aggregated from Fierce Pharma's public RSS feed. The full reporting belongs to Fierce Pharma — please read it on their site.